Combined Detection of Serum Heat Shock Protein-90&amp;lt;i&amp;gt;α&amp;lt;/i&amp;gt; and Prostate Specific Antigen for Prostate Cancer Diagnosis

Shichang Zhang,Jiang Zheng

doi:10.4236/ym.2020.44026

Abstract

Objective: To explore the relationship between heat shock protein-90α (HSP-90α) and occurrence of prostate cancer, and clinical value of combined detection of serum HSP-90α and prostate specific antigen (PSA) in the diagnosis of prostate cancer. Method: A total of 30 patients with prostate cancer, 30 patients with benign prostatic hyperplasia (BPH) and 30 healthy men (control group) were selected from September 2018 to September 2019, then to detect levels of serum HSP-90α, total PSA and free PSA (FPSA) by ELISA, serum testosterone level by radioimmunoassay, prostate cancer tissue was removed by operation, and relative expression of tissue HSP-90α protein by Western blot. Results: The levels of serum HSP-90α and total PSA in prostate cancer group were significantly higher than other two groups, and testosterone level was lower than other two groups (P 0.05). It was found by Pearson test that serum HSP-90α was positively correlated with total PSA level (r = 0.659, P = 0.005), while negatively correlated with testosterone level (r = -0.549, P = 0.006). According to TNM stage of prostate cancer, there were 17 cases of stage I - II, 13 cases of stage III - IV, 6 cases of Gleason score 1 - 4, 13 cases of 5 - 7, 11 cases of 8 - 10, tumor diameter range from 0.8 to 6.2 cm, with average of (3.9 ± 1.5) cm. The relative expression of HSP-90α protein in tumor tissue was closely related to TNM stage, Gleason score and tumor diameter (P α and PSA levels for prostate cancer diagnosis was 0.896, and that of single PSA detection was 0.852. Conclusion: Higher expressions of HSP-90α in prostate cancer tissue and serum may be closely related to occurrence and development of prostate cancer, and combined detections of serum HSP-90α and PSA levels are of great significance in improving early diagnosis of prostate cancer.

Highlights

Prostate cancer is the second most common malignant tumor in men, with a rapid increase in recent years, increasing with age [1]
A total of 30 patients with prostate cancer, 30 patients with benign prostatic hyperplasia (BPH) and 30 healthy men were selected from September 2018 to September 2019, to detect levels of serum heat shock protein-90α (HSP-90α), total prostate specific antigen (PSA) and free PSA (FPSA) by ELISA, serum testosterone level by radioimmunoassay, prostate cancer tissue was removed by operation, and relative expression of tissue HSP-90α protein by Western blot
Higher expressions of HSP-90α in prostate cancer tissue and serum may be closely related to occurrence and development of prostate cancer, and combined detections of serum HSP-90α and PSA levels are of great significance in improving early diagnosis of prostate cancer

Summary

Introduction

Prostate cancer is the second most common malignant tumor in men, with a rapid increase in recent years, increasing with age [1]. The diagnosis and TNM staging of Prostate cancer are mainly based on prostate specific antigen (PSA) level, MRI, biopsy of Prostate biopsy, and isotopic bone scan, etc., which are the main basis for the diagnosis and treatment of Prostate cancer clinically [2]. With the in-depth study on the molecular mechanism of tumor development, it has been found that Heat shock protein-90 (HSP-90) may be activated through multiple signaling pathways in the process of prostate cancer carcinogenesis, which is closely related to the occurrence, development, treatment and prognosis of prostate cancer [4] [5]. This study mainly discussed the relationship between HSP-90 and the incidence of prostate cancer, and the clinical value of combined detection of serum HSP-90 and PSA in the diagnosis of prostate cancer

Methods

Results

Discussion

Conclusion